3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Unknown
1
Recruiting
1
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Dermatologic
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
958
Urinary Bladder Neoplasms
264
Carcinoma, Renal Cell
251
Kidney Neoplasms
146
Carcinoma, Transitional Cell
130
Breast Neoplasms
128
Neoplasms
122
Colorectal Neoplasms
97
Ovarian Neoplasms
91
Melanoma
86
Carcinoma, Non-Small-Cell Lung
84
Lung Neoplasms
81
Neoplasm Metastasis
79
Pancreatic Neoplasms
68
Non-Muscle Invasive Bladder Neoplasms
68
Uterine Cervical Neoplasms
58
Stomach Neoplasms
55
Head and Neck Neoplasms
51
Squamous Cell Carcinoma of Head and Neck
47
Endometrial Neoplasms
47
Adenocarcinoma
46
Esophageal Neoplasms
44
Testicular Neoplasms
42
Sarcoma
41
Carcinoma, Hepatocellular
41
Disease
33
Triple Negative Breast Neoplasms
32
Liver Neoplasms
30
Colonic Neoplasms
29
Metastatic Castration-resistant Prostate Cancer
25
Interventions
pembrolizumab
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colitis, Ulcerative
×
Genitourinary
×
Clear all
NCT07223424
2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2
Recruiting
880 enrolled